{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:17:12Z","timestamp":1780435032723,"version":"3.54.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Vascular endothelial growth factor (VEGF) contributes to angiogenesis and vasculogenesis. The occurrence and progression of tumors are accompanied by angiogenesis. Vascular endothelial growth factor inhibitors (VEGFI) have been used in anti-tumor treatment. However, aortic dissection (AD) is one of the VEGFI-associated adverse reactions with cute onset, rapid progression, and high case fatality rate. We collected case reports of VEGFI related to aortic dissection in PubMed and CNKI (China National Knowledge Infrastructure) from inception to 28 April 2022. Seventeen case reports were selected. The medication included sunitinib, sorafenib, pazopanib, axitinib, apatinib, anlotinib, bevacizumab, and ramucirumab. This review discusses the pathology, risk factors, diagnosis, and treatment of AD. Vascular endothelial growth factor inhibitors are related to aortic dissection. Although current literature lacks clear statistical evidence on the population, we offer points to encourage further confirmation of the best methods of care for these patients.<\/jats:p>","DOI":"10.3389\/fphar.2023.1189910","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T12:29:51Z","timestamp":1687609791000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Aortic dissection induced by vascular endothelial growth factor inhibitors"],"prefix":"10.3389","volume":"14","author":[{"given":"Shuqi","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/jcb.30344","article-title":"Molecular mechanism of VEGF and its role in pathological angiogenesis","volume":"123","author":"Ahmad","year":"2022","journal-title":"J. Cell. Biochem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1080\/02841860801978905","article-title":"Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab","volume":"47","author":"Aragon-Ching","year":"2008","journal-title":"Acta Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1002\/ccr3.1674","article-title":"Successful treatment of aortic dissection during sorafenib therapy for hepatocellular carcinoma","volume":"6","author":"Atsunori","year":"2018","journal-title":"Clin. Case Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/annonc\/mdp468","article-title":"Acute aortic dissection during sorafenib-containing therapy","volume":"21","author":"Carles","year":"2010","journal-title":"Ann. Oncol. Official J. Eur. Soc. Med. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(22)01970-5","article-title":"Acute aortic dissection","volume":"401","author":"Carrel","year":"2023","journal-title":"Lancet (London, Engl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/1358863X211006470","article-title":"Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the fda adverse event reporting system and published in the literature","volume":"26","author":"Cheng","year":"2021","journal-title":"Vasc. Med. Lond. Engl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11912-013-0368-7","article-title":"Aflibercept--a decoy VEGF receptor","volume":"16","author":"Ciombor","year":"2014","journal-title":"Curr. Oncol. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/s0022-5223(19)33323-9","article-title":"Surgical management of dissecting aneurysms of the aorta","volume":"49","author":"Debakey","year":"1965","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/CS20200305","article-title":"Cardiotoxic effects of angiogenesis inhibitors","volume":"135","author":"Dobbin","year":"2021","journal-title":"Clin. Sci. (Lond)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e00707","DOI":"10.1002\/prp2.707","article-title":"Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis","volume":"9","author":"D\u00f6rks","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/annonc\/mdp480","article-title":"Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma","volume":"21","author":"Edeline","year":"2009","journal-title":"Ann. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1590\/1516-3180.2013.7380002","article-title":"Aortic dissection during antiangiogenic therapy with sunitinib. A case report","volume":"133","author":"Formiga","year":"2014","journal-title":"Sao Paulo Med. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3971\/j.issn.1000-8578.2019.18.1957","article-title":"Aortic dissection in apatinib treatment of advanced hepatocellular carcinoma: A case report","volume":"46","author":"Fubo","year":"2019","journal-title":"Cancer Res. Prev. Treat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00280-013-2131-z","article-title":"Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models","volume":"71","author":"Gozgit","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.cjca.2017.03.002","article-title":"Potential sunitinib-induced coronary artery and aortic dissections","volume":"33","author":"Hatem","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/hrt.2005.078550","article-title":"Diagnosis and management of patients with aortic dissection","volume":"93","author":"Ince","year":"2007","journal-title":"Heart (British Card. Soc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/1759-7714.13288","article-title":"Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma","volume":"11","author":"Jiang","year":"2020","journal-title":"Thorac. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1517\/13543784.2013.775243","article-title":"Axitinib for the treatment of advanced non-small-cell lung cancer","volume":"22","author":"King","year":"2013","journal-title":"Expert Opin. Investigational Drugs"},{"key":"B22","first-page":"1815","article-title":"A case of aortoesophageal fistula rupture due to descending thoracic aortic dissection with recurrent colon cancer during chemotherapy containing bevacizumab","volume":"43","author":"Koda","year":"2016","journal-title":"Gan Kagaku Ryoho"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1055\/s-0033-1363274","article-title":"Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years","volume":"45","author":"Kurtz","year":"2014","journal-title":"Aktuelle Urol."},{"key":"B25","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"9134","DOI":"10.1158\/0008-5472.CAN-05-4290","article-title":"KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties","volume":"66","author":"Nakamura","year":"2006","journal-title":"Cancer Res."},{"key":"B27","first-page":"981","article-title":"A thoracic aortic dissection case during treatment with ramucirumab plus nab-paclitaxel","volume":"47","author":"Nikai","year":"2020","journal-title":"Gan kagaku ryoho"},{"key":"B28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/0284186X.2014.963887","article-title":"Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib","volume":"54","author":"Niwa","year":"2015","journal-title":"Acta Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1161\/CIRCULATIONAHA.116.025144","article-title":"Association between aortic dissection and systemic exposure of vascular endothelial growth factor pathway inhibitors in the Japanese adverse drug event report database","volume":"135","author":"Oshima","year":"2017","journal-title":"Circulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1158\/1535-7163.MCT-05-0333","article-title":"SU14813: A novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity","volume":"5","author":"Patyna","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-05-4665","article-title":"AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts","volume":"66","author":"Polverino","year":"2006","journal-title":"Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11523-016-0419-8","article-title":"Ramucirumab clinical development: An emerging role in gastrointestinal tumors","volume":"11","author":"Sanchez-Gastaldo","year":"2016","journal-title":"Target. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: A novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Curr. Oncol. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3760\/cma.j.issn.1001-4497.2017.11.001","article-title":"Chinese experts\u2019 consensus of standardized diagnosis and treatment for aortic dissection","volume":"33","author":"Surgeon","year":"2017","journal-title":"Chin. J. Thorac. Cardiovasc Surg."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1536\/ihj.17-461","article-title":"Aortic dissection and cardiac dysfunction emerged coincidentally during the long-term treatment with angiogenesis inhibitors for metastatic renal cell carcinoma","volume":"59","author":"Takada","year":"2018","journal-title":"Int. Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e245653","DOI":"10.1136\/bcr-2021-245653","article-title":"Vascular endothelial growth factor tyrosine kinase inhibitor targeted therapy: A potential cause of an acute aortic dissection lesser known to the emergency physician","volume":"14","author":"Ting","year":"2021","journal-title":"BMJ Case Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jvscit.2018.02.003","article-title":"Acute aortic dissection with sporadic aortic calcifications during chemotherapy with sunitinib","volume":"4","author":"Toru","year":"2018","journal-title":"J. Vasc. Surg. Cases Innovative Tech."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e020844","DOI":"10.1161\/JAHA.121.020844","article-title":"Aneurysm and artery dissection following the use of vascular endothelial growth factor inhibitor: A real-world analysis using a spontaneous reporting system","volume":"10","author":"Wang","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Res."},{"key":"B41","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: A multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"B45","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration","volume":"60","author":"Wood","year":"2000","journal-title":"Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/j.clinre.2016.12.005","article-title":"Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma","volume":"41","author":"Xu","year":"2017","journal-title":"Clin. Res. Hepatology Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101249","DOI":"10.1016\/j.cpcardiol.2022.101249","article-title":"Research progress on the pathogenesis of aortic dissection","volume":"48","author":"Yin","year":"2022","journal-title":"Curr. Problems Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/ejhpharm-2019-001879","article-title":"Aortic dissection after ramucirumab infusion","volume":"27","author":"Zenoni","year":"2019","journal-title":"Eur. J. Hosp. Pharm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1189910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T12:29:59Z","timestamp":1687609799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1189910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":48,"alternative-id":["10.3389\/fphar.2023.1189910"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1189910","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"article-number":"1189910"}}